If approved, Eylea would be the first treatment for RVO with 8-week dosing. The FDA target action date is Aug. 19, 2025.

The US Food and Drug Administration (FDA) has accepted Regeneron Pharmaceuticals’ supplemental biologics licence application ...

Botsch's research helps parents and health care providers decide whether or not to continue patching their children who were ...

Regeneron aims for FDA approval of extended dosing for EYLEA HD in AMD and DME, with a decision by April 2025. Pre-filled ...

A health condition that requires immediate medical attention to protect eyesight, one has to be particularly careful in ...

So the symptoms of retinal vein occlusion can vary. So the first thing is, the patient might tell me that they have a certain hemisphere of their vision that's involved or a small little scotoma ...

Bayer seeks EMA approval for aflibercept 8 mg for treatment of retinal vein occlusion: Berlin Thursday, April 10, 2025, 16:00 Hrs [IST] Bayer has submitted an application to the E ...

With vision loss due to diabetes emerging as one of the most serious yet overlooked complications in India, Firstpost brings ...